Q2 2026 saw 7% sales growth and improved margins, driven by medical and industrial markets, with net earnings up 3.4% year-over-year. Cash flow and liquidity remain strong, and a CEO transition was announced. Environmental remediation and share repurchases were notable developments.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.